PharmaCyte Biotech Inc (PMCB)

[Peacefulwendy]

You have to understand this from a historical perspective, and read between the lines. Our intent from the very beginning was to pick up where Austrianova left off. We were going to continue using Australia based CNS as our CRO. In fact, if you listen to the previous radio interviews, you will hear us say that we are not even going after FDA immediately. We were going to just work in the overseas arena.

Then, in January 2014, we got an email from Dr Von Hoff wanting to get involved with testing CiaB at TD2. We decided on two separate treatments, phase 1 trials, based on TD2s research, pain and malignant ascites.

Now, with TD2s continued interest and support, we are going to be conducting trials with their access to, most likely, every PC patient in the US and Europe. So now we have access to so many more patients and a new trial design that sets us up beautifully for FDA approval.

So, you can hang your hat on the fact that we realized that the new trial design and the multitude of patient access we get through TD2 caused us to go with them for our next phase or you can move forward and know that this was the right move AND it is obvious that the guidance we are getting from our new partners is more noteworthy than that inconsequential point...